Nitya Krishnan1, Timothy McAlindon2,
Melynn Nuite, Kimberly Carr, Deborah Burstein1,3, Lori Lyn Price,
Klaus Flechsenhar4
1Department of Radiology, Beth Israel
Deaconess Medical Center, Boston, MA, United States; 2Division of
Rheumatology, Tufts Medical Center, Boston, MA, United States; 3Health
Sciences and Technology , Harvard Medical School, Boston, MA, United States; 4Research & Development, Gelita AG, Eberbach,
Germany
A
pilot study was performed to determine if dGEMRIC or T2-mapping could detect
changes in knee cartilage among participants treated with collagen
hydrolysate (Fortigel) versus placebo. A randomized, double-blind, 24-week
clinical trial included 30 participants with symptomatic knee OA. Half
received 10 grams collagen hydrolysate orally. The dGEMRIC index was able to
discriminate between treatment and placebo groups in the tibial regions with
an increase in dGEMRIC in the active arm. The sample size was small, and so
these data are preliminary.
Keywords